Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Colgate Oral Pharmaceuticals, Inc.
WARNING LETTER
•Colgate Oral Pharmaceuticals, Inc.•August 21, 2014

Colgate Oral Pharmaceuticals, Inc. – FDA Warning Letter, Aug 21, 2014

Record Details

The FDA issued a Warning Letter to Colgate Oral Pharmaceuticals, Inc. for non-compliance with the Generic Drug User Fee Amendments of 2012 (GDUFA). The facility failed to pay the required annual facility fees for fiscal years 2013 and 2014, despite self-identifying as a drug manufacturing facility. This failure constitutes a violation of GDUFA (21 U.S.C. §§ 379j-41 to 379j-42). As a direct consequence, all finished dosage forms of drugs and active pharmaceutical ingredients (APIs) manufactured at the facility are considered misbranded under 21 U.S.C. §§ 352(aa) and 379j-42(g)(4)(A)(iii). Shipping these misbranded products in interstate commerce, including importation into the U.S., is a violation of federal law (21 U.S.C. § 331(a)). The FDA has placed the facility on a publicly available GDUFA facility arrears list. Significant business implications include the non-receipt of any generic drug submissions from Colgate or its affiliates, and new generic drug submissions referencing the facility will also not be received unless outstanding fees are paid within 20 calendar days. The company is required to take prompt action by immediately paying the outstanding 2013 and 2014 fees. Failure to correct these violations may lead to further regulatory actions such as seizure, injunction, or placement on import alert, resulting in refusal of admission for their drugs into the United States. A written response detailing corrective actions is required within 15 working days.

Company
Colgate Oral Pharmaceuticals, Inc.
Inspection date
August 21, 2014
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Michael M. Levy
View Company Profile

ID · 3ff1449e-7be6-41b9-9f27-429779f5337b

Violation Codes10
21 U.S.C. 379j-4121 U.S.C. 379j-4221 U.S.C. 379j-41(5)(A)(i)21 U.S.C. 379j-42(f)21 U.S.C. 379j-42(a)(4)21 U.S.C. 379j-42(l)21 U.S.C. 352(aa)21 U.S.C. 379j-42(g)(4)(A)(iii)21 U.S.C. 33221 U.S.C. 334

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Colgate Oral Pharmaceuticals, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.